Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies

Purpose Patients with malignancy sometimes develop painful mucositis and require patient-controlled analgesia (PCA) to treat their pain. Pain disrupts sleep and there is some evidence that analgesic medications also disrupt sleep. This study examined whether treatment with the sedative hypnotic eszo...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2011-12, Vol.19 (12), p.2015-2020
Main Authors: Dimsdale, Joel E., Ball, Edward D., Carrier, Ewa, Wallace, Mark, Holman, Peter, Mulroney, Carolyn, Shaikh, Farah, Natarajan, Loki
Format: Article
Language:English
Subjects:
Adult
Analysis
Azabicyclo Compounds - administration & dosage
Azabicyclo Compounds - therapeutic use
Cancer
Care and treatment
Digestive system
Drug therapy
Eszopiclone
Fatigue - chemically induced
Hematologic Neoplasms - complications
Humans
Hypnotics and Sedatives - administration & dosage
Hypnotics and Sedatives - therapeutic use
Insomnia
Medical disorders
Medicine
Medicine & Public Health
Middle Aged
Morphine
Mucositis - complications
Mucositis - etiology
Mucositis - physiopathology
Mucous membrane
Nursing
Nursing Research
Oncology
Original
Original Article
Pain
Pain - drug therapy
Pain - etiology
Pain management
Pain Medicine
Piperazines - administration & dosage
Piperazines - therapeutic use
Rehabilitation Medicine
Sleep - drug effects
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Patients with malignancy sometimes develop painful mucositis and require patient-controlled analgesia (PCA) to treat their pain. Pain disrupts sleep and there is some evidence that analgesic medications also disrupt sleep. This study examined whether treatment with the sedative hypnotic eszopiclone could improve self-reports of sleep, fatigue, and pain as well as decrease opioid self-administered via PCA. Methods Inpatients who developed mucositis severe enough to require PCA treatment were randomized double-blind to a 2-day trial on eszopiclone or placebo-administered at bedtime. Patients completed questionnaires which assessed sleep, pain, and fatigue. PCA medication was calculated in terms of morphine equivalents. Data were analyzed with unpaired t tests and repeated measures analysis of variance. Results Twenty-two patients were randomized to placebo and 23 to eszopiclone. Groups were comparable in age and treatment characteristics. Mean pain scores were lower in the eszopiclone group at all time points (morning p  = 0.01, afternoon p  = 0.04, evening p  = 0.04). The eszopiclone group reported increased sleep time ( p  
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-010-1052-1